This review examines the potential of melanocortin-based therapies, such as bremelanotide, in treating sexual dysfunction in both men and women. Melanocortinergic agents, which activate melanocortin receptors in the brain, specifically the hypothalamus, have been shown to enhance sexual desire, arousal, and erectile function. Clinical trials, including Phase II studies, have
